Further, our results showed that studies using IHC to detect ALCAM expression predicted poorer outcomes of CRC patients (HR = 3.07, 95%CI = 1.97–4.76, P = 0.0002) compared to studies using tissue microarray (TMA) to estimate ALCAM levels (HR = 1.01, 95%CI = 0.78–1.30, P = 0.45). This evidence concerns the gene ALCAM and colorectal carcinoma.